

9200

PAV 1610

122

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 5,565,467

Date of Issue: July 31, 1996

Name of Patentee: Kenneth William BATCHELOR, et al.

Title of Invention: ANDROSTENONE DERIVATIVE

Assistant Commissioner for Patents
Washington, D.C. 20231

Attention: solicitor (M.P.E.P. § 1002.02(k))

RECEIVED
TECH CENTER 1600/2900
99 JUN - 1 PM 1:38**PETITION FOR CORRECTION OF INVENTORSHIP OF PATENT
(37 C.F.R. § 1.324)**

1. This is a petition for correction of error in a misjoinder of inventors in the above issued patent. It is respectfully requested that the PTO issue a certificate correcting the error.
2. Enclosed herewith is (37 C.F.R. § 1.324(b)):
 - A. a statement from each person who is being deleted as an inventor that the inventorship error occurred without any deceptive intention on his or her part.
 - B. A statement from the current named inventors who have not submitted a statement under A. above:
 - Agreeing to the change of inventorship
 - Stating that there is no disagreement in regard to the requested change.
3. Also enclosed is the written consent of the assignee.
4. The fee required (37 C.F.R. § 1.20(b)) is paid as follows:

Please charge Deposit Account No. 07-1392 in the amount of \$130.00.

05/27/1999 STEFERRA 00000015 071392 5565467
01 FC:122 130.00 CH

Please charge any shortage in the fees or credit any overpayment to deposit

Account No. 02-1392 pursuant to 37 C.F. R. § 1.16 or 1.17.

Respectfully submitted,

GLAXO WELLCOME INC.

By: Robert H. Brink
Robert H. Brink
Registration No. 36,094

Dated: May 17, 1999
Glaxo Wellcome Inc.
5 Moore Drive
Research Triangle Park, NC 27709
Telephone: (919) 483-3323
Facsimile: (919) 483-7988

RECEIVED
TECH CENTER 1600/2900
99 JUN - 1 PM 1:38

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER OF PATENTS AND TRADEMARKS,
WASHINGTON, D.C. 20231 ON _____
IN ACCORDANCE WITH THE PROVISIONS OF 37 CFR 1.8.

SIGNATURE

PRINTED NAME

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTEE: Kenneth William BATCHELOR, et al.

PATENT NO.: 5,565,467

ISSUED: July 31, 1996

TITLE: ANDROSTENONE DERIVATIVE

**STATEMENT UNDER 37 CFR §1.48(a) OF NO
DECEPTIVE INTENT IN FAILING TO NAME INVENTOR**




Assistant Commissioner for Patents
Washington, D.D. 20231

Sir:

I, Robert a. Mook, Jr. do hereby declare and say as follows:

At the time of filing the application for the above patent, I was named as an inventor. However, the claims for which I was an inventor were deleted during prosecution and are not contained in the above patent. The error in inventorship of the instant patent application occurred without any deceptive intent on my part.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued therefrom.


Robert A. Mook, Jr.

5 May 99
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTEE: Kenneth William BATCHELOR, et al.

PATENT NO.: 5,565,467

ISSUED: July 31, 1996

TITLE: ANDROSTENONE DERIVATIVE

**STATEMENT UNDER 37 CFR §1.48(a) OF NO
DECEPTIVE INTENT IN FAILING TO NAME INVENTOR**


Assistant Commissioner for Patents
Washington, D.D. 20231


Sir:

I, George F. Dorsey, Jr., do hereby declare and say as follows:

At the time of filing the application for the above patent, I was named as an inventor. However, the claims for which I was an inventor were deleted during prosecution and are not contained in the above patent. The error in inventorship of the instant patent application occurred without any deceptive intent on my part.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued therefrom.


George F. Dorsey, Jr.


Date



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTEE: Kenneth William BATCHELOR, et al.

PATENT NO.: 5,565,467

ISSUED: July 31, 1996

TITLE: ANDROSTENONE DERIVATIVE



**STATEMENT UNDER 37 CFR §1.48(a) OF NO
DECEPTIVE INTENT IN FAILING TO NAME INVENTOR**

Assistant Commissioner for Patents
Washington, D.D. 20231

Sir:

I, Kenneth W. Batchelor, do hereby declare and say as follows:

At the time of filing the application for the above patent, I was named as an inventor. I agree with the requested change in inventorship to delete George F. Dorsey, Jr. and Robert A. Mook, Jr. from the above patent. The error in inventorship of the instant patent application occurred without any deceptive intent on my part.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued therefrom.

Kenneth W. Batchelor
Kenneth W. Batchelor

9th May 1999
Date

THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTEE: Kenneth William BATCHELOR, et al.

PATENT NO.: 5,565,467

ISSUED: July 31, 1996

TITLE: ANDROSTENONE DERIVATIVE

**STATEMENT UNDER 37 CFR §1.48(a) OF NO
DECEPTIVE INTENT IN FAILING TO NAME INVENTOR**




Assistant Commissioner for Patents
Washington, D.D. 20231

Sir:

I, Stephen V. Frye, do hereby declare and say as follows:

At the time of filing the application for the above patent, I was named as an inventor. I agree with the requested change in inventorship to delete George F. Dorsey, Jr. and Robert A. Mook, Jr. from the above patent. The error in inventorship of the instant patent application occurred without any deceptive intent on my part.


I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful, false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued therefrom.


Stephen V. Frye


Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 5,565,467
Date of Issue: July 31, 1996
Name of Patentee: Kenneth William BATCHELOR, et al.
Title of Invention: ANDROSTENONE DERIVATIVE



Assistant Commissioner for Patents
Washington, D.C. 20231

**CONSENT OF ASSIGNEE TO CHANGE OF INVENTORSHIP IN PATENT
(37 C.F.R. § 1.324)**

Glaxo Wellcome Inc., owner by assignment of the above patent, in the assignment recorded in the PTO on March 16, 1995 at Reel 7406, Frame 0967, hereby consents to the amendment of the inventorship of this patent as requested in the accompanying papers.

Attached is a Certificate Under 37 CFR §3.73(b), establishing the right of the assignee to take action in this case.

Respectfully submitted,

GLAXO WELLCOME INC.

By: Robert H. Brink
Robert H. Brink
Reg. No. 36,094

Dated: May 17, 1999
Glaxo Wellcome Inc.
5 Moore Drive
Research Triangle Park, NC 27709
Telephone: (919)483-3323
Facsimile (919)483-7988

CERTIFICATE UNDER 37 C.F.R. §3.73(b)

Applicant: Kenneth William BATCHELOR; Stephen V. FRYE; George F. DORSEY, Jr.; and Robert A. MOOK, Jr.

Patent No.: 5,565,467 Issued: July 31, 1996

For: ANDROSTENONE DERIVATIVE

Glaxo Wellcome Inc., a Corporation
(Name of Assignee) (Type of Assignee, e.g. corporation, partnership, university, etc.)



certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 7406, Frame 0967, or for which a copy thereof is attached.

B. ☐ A chain of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature: David J. Levy

Date: MAY 17, 1999

Name: David J. Levy

Title: V.P. Intellectual Property Counsel, Assistant Secretary,


DATE: 05/09/95
TO:



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

CHARLES E. DADSWELL
GLAXO INC.
LEGAL-PATENT GROUP
FIVE MOORE DRIVE
RTP, NC 27709

NO5B



UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT ASSIGNMENT PROCESSING SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT BRANCH, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231

ASSIGNOR:
FRYE, STEPHEN V.

DOC DATE: 03/16/95

ASSIGNOR:
MOOK, ROBERT A., JR.

DOC DATE: 03/16/95

ASSIGNOR:
DORSEY, GEORGE F., JR.

DOC DATE: 03/16/95

ASSIGNOR:
BATCHELOR, KENNETH W.

DOC DATE: 03/16/95

RECORDATION DATE: 03/16/95 NUMBER OF PAGES 005 REEL/FRAME 7406/0967

DIGEST: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNEE:
GLAXO INC.
LEGAL-PATENT GROUP
5 MOORE DRIVE
RTP, NC 27709

SERIAL NUMBER 8-405120
PATENT NUMBER

FILING DATE 03/16/95
ISSUE DATE 00/00/00


EXAMINER/PARALEGAL
ASSIGNMENT BRANCH
ASSIGNMENT/CERTIFICATION SERVICES DIVISION

ASSIGNMENT


I, Stephen Vernon Frye, for good and valuable consideration, receipt of which is hereby acknowledged, from GLAXO INC., a North Carolina corporation having its principal place of business in Research Triangle Park, NC, hereinafter called the Assignee, do hereby sell, assign and transfer unto the Assignee, its successors and assigns, the entire right, title and interest in, to and under an application for Letters Patent of the United States executed by us on the same date for:

ANDROSTENONE DERIVATIVE

and the inventions and any of them therein set forth and described, and any and all Letters patent of the United States and of countries foreign thereto which may be granted thereon or therefor including any continuation, division, renewal, substitute, reissue or extension thereof or any legal equivalent thereof.

For the above consideration, I agree promptly upon request of the Assignee, its successors or assigns, to execute and deliver without further compensation any power of attorney, continuation or reissue, or other papers which may be necessary or desirable fully to secure to the Assignee, its successors and assigns, the inventions and any of them described in said application and all patent rights therein, in the United States and in any country foreign thereto.


IN WITNESS WHERETO, I, Stephen Vernon Frye, hereunto set my hand and seal this 16 day of March, 1995



Stephen Vernon Frye

State of North Carolina
County of Durham

Before me this 16 day of March 1995,
personally appeared, Stephen V. Frye, who is to me
personally known, and acknowledged the foregoing
instrument of assignment to be his free act and deed.



Sharon Elizabeth Scott

Notary Public

My commission expires 11/15/97

REEL 7406 FRAME 969

ASSIGNMENT

I, Robert A. Mook, Jr., for good and valuable consideration, receipt of which is hereby acknowledged, from GLAXO INC., a North Carolina corporation having its principal place of business in Research Triangle Park, NC, hereinafter called the Assignee, do hereby sell, assign and transfer unto the Assignee, its successors and assigns, the entire right, title and interest in, to and under an application for Letters Patent of the United States executed by us on the same date for:

ANDROSTENONE DERIVATIVE

and the inventions and any of them therein set forth and described, and any and all Letters patent of the United States and of countries foreign thereto which may be granted thereon or therefor including any continuation, division, renewal, substitute, reissue or extension thereof or any legal equivalent thereof.


For the above consideration, I agree promptly upon request of the Assignee, its successors or assigns, to execute and deliver without further compensation any power of attorney, continuation or reissue, or other papers which may be necessary or desirable fully to secure to the Assignee, its successors and assigns, the inventions and any of them described in said application and all patent rights therein, in the United States and in any country foreign thereto.

IN WITNESS WHERETO, I, Robert A. Mook, Jr., hereunto set my hand and seal this 16 day of March, 1995.


Robert A. Mook, Jr.,

State of North Carolina
County of Durham

Before me this 16 day of March, 1995,
personally appeared, Robert A. Mook, Jr., who is to
me personally known, and acknowledged the
foregoing instrument of assignment to be his free act
and deed.


Notary Public

My commission expires 11/15/97

REEL 7406 FRAME 970

ASSIGNMENT


I, George F. Dorsey, Jr., for good and valuable consideration, receipt of which is hereby acknowledged, from GLAXO INC., a North Carolina corporation having its principal place of business in Research Triangle Park, NC, hereinafter called the Assignee, do hereby sell, assign and transfer unto the Assignee, its successors and assigns, the entire right, title and interest in, to and under an application for Letters Patent of the United States executed by us on the same date for:

ANDROSTENONE DERIVATIVE

and the inventions and any of them therein set forth and described, and any and all Letters patent of the United States and of countries foreign thereto which may be granted thereon or therefor including any continuation, division, renewal, substitute, reissue or extension thereof or any legal equivalent thereof.


For the above consideration, I agree promptly upon request of the Assignee, its successors or assigns, to execute and deliver without further compensation any power of attorney, continuation or reissue, or other papers which may be necessary or desirable fully to secure to the Assignee, its successors and assigns, the inventions and any of them described in said application and all patent rights therein, in the United States and in any country foreign thereto.

IN WITNESS WHERETO, I, George F. Dorsey, Jr., hereunto set my hand and seal this 16 day of March, 1995.


George F. Dorsey, Jr.

State of North Carolina
County of Durham

Before me this 16 day of March, 1995,
personally appeared, George F. Dorsey, Jr., who is to
me personally known, and acknowledged the
foregoing instrument of assignment to be his free act
and deed.



Notary Public
My commission expires 11/15/97

RECORDED
PATENT & TRADEMARK OFFICE

MAR 16 95

REEL 7406 FRAME 971

STATE OF NORTH CAROLINA



Department of The
Secretary of State

I, **RUFUS L. EDMISTEN**, Secretary of State of the State of North Carolina, do hereby certify that the following is a listing of all changes in the corporate name of the corporation named below, insofar as disclosed by the records of this office:
Original name at date of incorporation or authorization:

GLAXO INC.

State of Incorporation: North Carolina
Date of Incorporation or Authorization: 29 May 1985


Name Changes

Name change was effected by

<u>Document and date filed or issued:</u>	<u>Name changed to:</u>
Articles of Amendment filed 05 May 1995	Glaxo Wellcome Inc

I **FURTHER CERTIFY** that this certificate is in compliance with North Carolina General Statute §55-4-05 and may be recorded in the office of the Register of Deeds in the same manner as deeds, the former name of the corporation appearing in the "Grantor" index and the amended name of the corporation appearing in the "Grantee" index.

IN WITNESS WHEREOF, I have hereunto set my hand and affixed my official seal at the City of Raleigh, this 24th day of May, 1995.



Rufus L. Edmisten

Secretary of State